No Data
Tianmao Group: Tianmao Group\'s performance forecast for the first three quarters of 2024
hubei biocause pharmaceutical (000627.SZ) issued a forecasted loss, expecting a net loss of 0.315 billion yuan to 0.345 billion yuan in the first three quarters.
Hubei Biocause Pharmaceutical (000627.SZ) announced its performance forecast for the first three quarters of 2024, expecting the attributable net profit for the first three quarters to be above ...
hubei biocause pharmaceutical (000627.SZ): It is expected to incur a loss of 0.315 billion yuan to 0.345 billion yuan in the first three quarters.
Grailmeeting October 14th | Hubei Biocause Pharmaceutical (000627.SZ) announced the performance forecast for the first three quarters of 2024, with a net loss attributable to shareholders of the listed company of 0.345 billion yuan to 0.315 billion yuan, compared to a loss of 212.9954 million yuan in the same period last year; net profit loss after deducting non-recurring gains and losses of 0.344 billion yuan to 0.314 billion yuan, compared to a loss of 209.636 million yuan in the same period last year; basic earnings per share loss of 0.070 yuan/share to 0.064 yuan/share. In the third quarter of 2024, net profit attributable to shareholders of the listed company amounted to 20 million yuan.
Private Companies Invested in Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Copped the Brunt of Last Week's CN¥2.0b Market Cap Decline
Hubei Biocause Pharmaceutical's Insurance Unit Logs 29 Billion Yuan Premium Income in January-August Period; Shares Down 3%
Hubei Biocause Pharmaceutical (000627.SZ) subsidiary China Best Life Insurance Co., Ltd. accumulated premium income of approximately 29.03 billion yuan from January to August.
Hubei Biocause Pharmaceutical (000627.SZ) announced that its subsidiary, China Best Life Insurance Co., Ltd., has...
No Data
No Data